Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues - Clinical and experimental applications
Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues - Clinical and experimental applications
复制标题
DOI：
10.1111/j.1749-6632.1999.tb07687.x
复制
发表时间：
1999-01-01
期刊：
影响因子：
--
通讯作者：
Montana, S
中科院分区：
文献类型：
--
作者：
Zucker, S;Hymowitz, M;Montana, S
MMP的产生和活化之间的平衡以及TIMP对它们的抑制是癌症侵袭和转移的关键方面。基于组织中合成的MMP渗入血流的概念，我们检测了癌症患者血浆中的MMP水平。在结肠直肠癌、乳腺癌、前列腺癌和膀胱癌中，大多数侵袭性疾病患者的血浆明胶酶B水平升高，在晚期结直肠癌患者中，高水平的明胶酶B或TIMP复合物与缩短的生存期相关。我们提出这些测定可能在临床上用于表征选定种类的癌症的转移潜能。在类风湿性关节炎和系统性红斑狼疮（SLE）中，血清和血浆基质溶解素-1水平相似地增加3-5倍。SLE患者血清基质溶解素-1水平的波动与疾病活动性的变化不一致。在SLE中，基质溶解素-1可能是慢性组织修复过程的一个组成部分，而不是引起组织损伤的原因。根据这些观察结果，我们得出结论，血浆/血清MMP和TIMP水平的测量可能提供重要的数据，选择和以下患者考虑治疗药物干扰MMP活性。
The balance between production and activation of MMPs and their inhibition by TIMPs is a crucial aspect of cancer invasion and metastasis, On the basis of the concept that MMPs synthesized in tissues seep into the bloodstream, we have examined MMP levels in the plasma of patients with cancer, In colorectal, breast, prostate, and bladder cancer, most patients with aggressive disease have increased plasma levels of gelatinase B, In patients with advanced colorectal cancer, high levels of either gelatinase B or TIMP complex were associated with shortened survival, We propose that these assays may be clinically useful in characterizing metastatic potential in selected kinds of cancer, In rheumatoid arthritis and systemic lupus erythematosus (SLE), serum and plasma levels of stromelysin-1 were similar to 3-5 fold increased. Fluctuating serum stromelysin-1 levels in SLE did not correspond with change in disease activity. In SLE, stromelysin-1 may be a component of the chronic tissue repair process rather than being responsible for inciting tissue damage. On the basis of these observations, we conclude that measurement of plasma/serum MMP and TIMP levels may provide important data for selecting and following patients considered for treatment with drugs that interfere with MMP activity.